Phase III Comparison of Prophylactic Cranial Irradiation Versus Observation in Patients With Locally Advanced Non-Small-Cell Lung Cancer: Primary Analysis of Radiation Therapy Oncology Group Study RTOG 0214

被引:227
作者
Gore, Elizabeth M. [1 ]
Bae, Kyounghwa
Wong, Stuart J.
Sun, Alexander
Bonner, James A.
Schild, Steven E.
Gaspar, Laurie E.
Bogart, Jeffery A.
Werner-Wasik, Maria
Choy, Hak
机构
[1] Med Coll Wisconsin, Dept Radiat Oncol, Milwaukee, WI 53213 USA
关键词
TERM-FOLLOW-UP; BRAIN METASTASES; FAILURE PATTERNS; NEOADJUVANT CHEMOTHERAPY; MULTIMODALITY TREATMENT; CEREBRAL METASTASES; RANDOMIZED-TRIAL; HIGH-RISK; CARCINOMA; RADIOTHERAPY;
D O I
10.1200/JCO.2010.29.1609
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Purpose This study was conducted to determine if prophylactic cranial irradiation (PCI) improves survival in locally advanced non-small-cell lung cancer (LA-NSCLC). Patients and Methods Patients with stage III NSCLC without disease progression after treatment with surgery and/or radiation therapy (RT) with or without chemotherapy were eligible. Participants were stratified by stage (IIIA v IIIB), histology (nonsquamous v squamous), and therapy (surgery v none) and were randomly assigned to PCI or observation. PCI was delivered to 30 Gy in 15 fractions. The primary end point of the study was overall survival (OS). Secondary end points were disease-free survival (DFS), neurocognitive function (NCF), and quality of life. Kaplan-Meier and log-rank analyses were used for OS and DFS. The incidence of brain metastasis (BM) was evaluated with the logistic regression model. Results Overall, 356 patients were accrued of the targeted 1,058. The study was closed early because of slow accrual; 340 of the 356 patients were eligible. The 1-year OS (P = .86; 75.6% v 76.9% for PCI v observation) and 1-year DFS (P = .11; 56.4% v 51.2% for PCI v observation) were not significantly different. The hazard ratio for observation versus PCI was 1.03 (95% CI, 0.77 to 1.36). The 1-year rates of BM were significantly different (P = .004; 7.7% v 18.0% for PCI v observation). Patients in the observation arm were 2.52 times more likely to develop BM than those in the PCI arm (unadjusted odds ratio, 2.52; 95% CI, 1.32 to 4.80). Conclusion In patients with stage III disease without progression of disease after therapy, PCI decreased the rate of BM but did not improve OS or DFS.
引用
收藏
页码:272 / 278
页数:7
相关论文
共 42 条
[1]
Agresti A., 1990, CATEGORICAL DATA ANA
[2]
CONCURRENT CISPLATIN/ETOPOSIDE PLUS CHEST RADIOTHERAPY FOLLOWED BY SURGERY FOR STAGES IIIA(N2) AND IIIB NON-SMALL-CELL LUNG-CANCER - MATURE RESULTS OF SOUTHWEST-ONCOLOGY-GROUP PHASE-II STUDY-8805 [J].
ALBAIN, KS ;
RUSCH, VW ;
CROWLEY, JJ ;
RICE, TW ;
TURRISI, AT ;
WEICK, JK ;
LONCHYNA, VA ;
PRESANT, CA ;
MCKENNA, RJ ;
GANDARA, DR ;
FOSMIRE, H ;
TAYLOR, SA ;
STELZER, KJ ;
BEASLEY, KR ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :1880-1892
[3]
Andre F, 2001, CANCER, V91, P2394, DOI 10.1002/1097-0142(20010615)91:12<2394::AID-CNCR1273>3.3.CO
[4]
2-Y
[5]
EFFECT OF CHEMOTHERAPY ON LOCALLY ADVANCED NON-SMALL-CELL LUNG-CARCINOMA - A RANDOMIZED STUDY OF 353 PATIENTS [J].
ARRIAGADA, R ;
LECHEVALIER, T ;
QUOIX, E ;
RUFFIE, P ;
DECREMOUX, H ;
DOUILLARD, JY ;
TARAYRE, M ;
PIGNON, JP ;
LAPLANCHE, A .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 20 (06) :1183-1190
[6]
Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis [J].
Arrieta, Oscar ;
Saavedra-Perez, David ;
Kuri, Roberto ;
Aviles-Salas, Alejandro ;
Martinez, Luis ;
Mendoza-Posada, Daniel ;
Castillo, Patricia ;
Astorga, Alma ;
Guzman, Enrique ;
De la Garza, Jaime .
BMC CANCER, 2009, 9
[7]
Hopkins Verbal Learning Test Revised: Normative data and analysis of inter-form and test-retest reliability [J].
Benedict, RHB ;
Schretlen, D ;
Groninger, L ;
Brandt, J .
CLINICAL NEUROPSYCHOLOGIST, 1998, 12 (01) :43-55
[8]
A CONFIDENCE-INTERVAL FOR THE MEDIAN SURVIVAL-TIME [J].
BROOKMEYER, R ;
CROWLEY, J .
BIOMETRICS, 1982, 38 (01) :29-41
[9]
Does the incidence and outcome of brain metastases in locally advanced non-small cell lung cancer justify prophylactic cranial irradiation or early detection? [J].
Carolan, H ;
Sun, AY ;
Bezjak, A ;
Yi, QL ;
Payne, D ;
Kane, G ;
Waldron, J ;
Leighl, N ;
Feld, R ;
Burkes, R ;
Keshavjee, S ;
Shepherd, F .
LUNG CANCER, 2005, 49 (01) :109-115
[10]
Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment -: Risk factors analysis [J].
Ceresoli, GL ;
Reni, M ;
Chiesa, G ;
Carretta, A ;
Schipani, S ;
Passoni, P ;
Bolognesi, A ;
Zannini, P ;
Villa, E .
CANCER, 2002, 95 (03) :605-612